We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Opko Health Inc.
An SI Board Since February 2007
Posts SubjectMarks Bans Symbol
183 22 0 OPK
Emcee:  HEXonX Type:  Moderated
OPK - Opko Health Inc.

(was EXEG.OB - eXegenics)

3/27/07: Acuity Pharmaceuticals & Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market

2/9/07: eXegenics completed its sale of shares of common stock, constituting approximately 51% of the issued and outstanding shares of eXegenics capital stock, on a fully diluted basis, to a small group of investors led by Phillip Frost, M.D. #msg-18230877 The investors paid eXegenics an aggregate purchase price of $8.6 million at the closing. The purchase price is subject to adjustment based on eXegenics stockholders’ equity at the closing. The shares of eXegenics common stock sold were not registered under the Securities Act of 1933, and may not be offered or sold in the United States absent registration under the Securities Act or the availability of an exemption from registration.

10K filed 3/22/207 showing 36,550,369 shares as of 03/15/2007.


EXEG is a non-operating shell with about $9 million of cash on the books. Outstanding common shares = 17.0 million plus 1.0 million of preferred convertible to common.

The excitement is that Dr. Phillip Frost, a pharmaceutical billionaire, is buying 51% of the stock for cash.

On August 14, 2006, eXegenics, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with a group of investors led by Phillip Frost, M.D, for the sale of shares of the Company's common stock. The shares of common stock to be issued to the purchasers will constitute, upon issuance, 51% of the issued and outstanding shares of common stock of the Company, on a fully-diluted basis. The aggregate purchase price to be paid for the shares is $8,613,000, reflecting the book value of the Company at June 30, 2006

"Investors shall purchase from the Company, an aggregate of 19,440,491" Current outstanding, before the transaction, is

Currently, eXegenics is a shell company. It was formerly known as Cytoclonal Pharmaceutics which was previously involved in researching cancer drugs. However, the co has terminated all research activities. All scientific staff and administrative positions were eliminated. The co has established a committee to study strategic direction and identify potential business opportunities.

Frost is the man behind Ivax Corporation, a generic drug manufacturer,m which was recently acquired by Teva. Frost's company had repeatedly gone to court to fight for the right to produce generic versions of brand-name drugs with expiring patents.

Dr. Phillip Frost was named Vice Chairman of the Board of Teva Pharmaceutical Industries, Ltd. ("Teva") in January 2006 when Teva acquired IVAX Corporation. Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1990.

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
183FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 PatienJulius Wong-June 1
182Here's Why You Should Invest in OPKO Health (OPK) Stock Now Wong-May 29
18152-week high, one of a series, possibly the 4th.Sr K-March 6
180Novitas Issues Final Local Coverage Determination for the 4Kscore® Test fiJulius Wong-11/15/2019
179OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an InJulius Wong-10/21/2019
178Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test Julius Wong-6/30/2019
177Frost buying again.
176Looks like Frost was a buyer yesterday.Bearcatbob-2/7/2017
175Anyone have any idea of what unannounced news is out there today?Bearcatbob-2/6/2017
174The Buffett of Biotech's Portfolio forbes.comJulius Wong-1/16/2017
173The Company’s J.P. Morgan 35th Annual Healthcare Conference presentation slides Julius Wong-1/10/2017
172OPK fell 18.85% to $9.30 on that news. The company's news release: financeSr K-12/31/2016
171Opko Health reports disappointing results in late-stage trial of human growth hoJulius Wong-12/30/2016
1709:29 AM OPKO Health (OPK) announces that it has been selected for addition to thSr K-12/19/2016
169I know of no other stock in the market that provides the risk/reward Opko does. more100-8/9/2016
168Opko Health (OPK +1.55%) rose nearly 4% in after-hours trading after a FDA appromore100-6/22/2016
167OPKO Health beats by $0.01, beats on revenue OPKO Health (NYSE: OPK): Q1 EPS of Julius Wong-5/9/2016
166OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug ApplJulius Wong-3/30/2016
165OPK had a good size early slump yesterday after reporting its 4thQ and yearly rJibacoa-3/2/2016
164OPK is trading above the $9 level again.<g> Besides the presentation in N.Jibacoa-2/25/2016
163OPK opened with an UG and is trading above its February Hs and its Jan6 Lows.<Jibacoa-2/22/2016
162OPK closed up 8.34% on volume of 4,098,021 about 294Ks below its ADV.<g> Jibacoa-2/4/2016
161OPK is still trying to get back above its EMA10.<g> Today's volume is Jibacoa-1/25/2016
160OPK has been able to stay on its last uptrend that started on Nov9, when it wasJibacoa-12/7/2015
159OPK opened with a small UG, and it was able to trade above its Nov12 H of 11.4Jibacoa-12/3/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):